CompareAtomwisevsRecursion

Atomwise is an AI-powered drug discovery platform that helps pharmaceutical and biotechnology organisations identify potential small-molecule medicines using deep learning. Built for research teams rather than individual users, it combines virtual screening, structure-based modelling and biological data analysis to support early-stage drug discovery.

• Built for pharmaceutical and biotechnology organisations seeking to accelerate small-molecule drug discovery with AI.

• Uses AtomNet deep learning technology to identify potential drug targets, screen compounds and support structure-based drug design.

• Supports drug discovery across multiple therapeutic areas through research partnerships with pharmaceutical companies.

• Available through partnership agreements rather than self-service, with custom pricing and implementation tailored to each organisation.

Atomwise is best suited to pharmaceutical and biotechnology organisations investing in AI-assisted drug discovery, although its partnership-based model may be less suitable for smaller research teams looking for self-service software.

Recursion is an AI drug discovery company that uses cellular imaging, automation, and machine learning to identify and validate new drug candidates. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.

The clearest fit for Recursion is pharma collaborators and internal pipeline programs, with the platform leaning into phenomics platform with multimodal data. Limitations are real: direct buyer access is limited to partnerships. Pricing is sales-led and scoped per buyer rather than posted publicly. Buyers should confirm validation depth, support coverage, and rollout plan before signing.